Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach

• URL: http://arxiv.org/abs/2305.18088v7
• Date: Sun, 23 Jun 2024 17:03:26 GMT
• Title: Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach
• Authors: Imra Aqeel, Abdul Majid,
• Abstract summary: The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2. We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities.
• Score: 0.15346678870160887
• License: http://creativecommons.org/licenses/by-sa/4.0/
• Abstract: The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. Progressively, drug repurposing is emerging a promise solution as it saves the time, cost and labor. However, the number of drug candidates that have been identified as being repurposed for the treatment of COVID-19 are still insufficient, so more effective and thorough drug exploring strategies are required. In this study, we joint the molecular docking with machine learning regression approaches to find some prospective therapeutic candidates for COVID-19 treatment. We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2, which is responsible to replicate the virus. Molecular docking is used to calculate the binding affinities of these drugs to the main protease 3CL. We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities. Our outcomes demonstrated that the Decision Tree Regression (DTR) model with best scores of R2 and RMSE, is the most suitable model to explore the potential drugs. We shortlisted six favorable drugs. These drugs have novel repurposing potential, except for one antiviral ZINC203757351 compound that has already been identified in other studies. We further examined the physiochemical and pharmacokinetic properties of these most potent drugs and their best binding interaction to specific target protease 3CLpro. Our verdicts contribute to the larger goal of finding effective cures for COVID-19, which is an acute global health challenge. The outcomes of our study provide valuable insights into potential therapeutic candidates for COVID-19 treatment.

Related papers

• To Explore the Potential Inhibitors against Multitarget Proteins of COVID 19 using In Silico Study [0.0]
  The global pandemic due to emergence of COVID 19 has created the unrivaled public health crisis. We used the combination of molecular docking and machine learning regression approaches to explore the potential inhibitors for the treatment of COVID 19. We proposed five novel promising inhibitors with their respective Zinc IDs ZINC (3873365, 85432544, 8214470, 85536956, and 261494640) within the range of -19.7 kcal/mol to -12.6 kcal/mol.
  arXiv  Detail & Related papers  (2024-09-24T22:19:56Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Heterogeneous network-based drug repurposing for COVID-19 [7.097880564431694]
  The Corona Virus Disease 2019 (COVID-19) belongs to human coronaviruses (HCoVs), which spreads rapidly around the world. Compared with new drug development, drug repurposing may be the best shortcut for treating COVID-19. We constructed a comprehensive heterogeneous network based on the HCoVs-related target proteins and use the previously proposed deepDTnet to discover potential drug candidates for COVID-19.
  arXiv  Detail & Related papers  (2021-07-20T01:24:40Z)
• Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline [47.453507636022444]
  SARS-CoV-2, the causative virus of COVID-19 continues to cause an ongoing global pandemic. Drug repurposing provides an opportunity to deploy drugs for COVID-19 more rapidly than developing novel therapeutics. This in silico study uses structural similarity to clinical trial drugs to identify two drugs with potential applications to treat early COVID-19.
  arXiv  Detail & Related papers  (2021-07-05T13:08:24Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing [14.112444998191698]
  We propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible.
  arXiv  Detail & Related papers  (2020-12-03T18:34:10Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)
• Repurpose Open Data to Discover Therapeutics for COVID-19 using Deep Learning [22.01390057543923]
  There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic. There are currently no proven effective medications against COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19.
  arXiv  Detail & Related papers  (2020-05-21T16:02:29Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.